基线计算机断层扫描筛查与血液microRNA可预测肺癌风险并在BioMILD试验中定义合适筛查间隔
BioMILD前瞻性研究纳入4119名志愿者,中位随访5.3年,评估基线低剂量CT(LDCT)联合血液microRNA特征分类器(MSC)对肺癌发病与死亡的预测价值及个体化筛查间隔的意义。基线LDCT与MSC将参与者分为四组,4年肺癌发生率从CT-/MSC-的0.8%至CT+/MSC+的20.1%,5年肺癌死亡率从0.5至10.1。联合使用可预测个体肺癌发生与死亡,MSC对LDCT阳性者影响显著。
要点
- 基线LDCT联合血液MSC可将筛查人群分为四组,4年肺癌发生率0.8%至20.1%不等。
- CT+者4年肺癌发生率较CT-者高15.8倍(95%CI 10.34-24.05)。
- MSC+者4年肺癌发生率较MSC-者高2.0倍(95%CI 1.40-2.90),CT+与CT-间MSC效应无差异证据。
核心结论
- 基线LDCT联合血液miRNA可预测个体肺癌发生与死亡,MSC对LDCT阳性者影响显著,可能对个体化筛查间隔有重要意义。
研究设计与样本
- 前瞻性BioMILD研究于2013年1月至2016年3月入组4119名志愿者,中位随访5.3年。
- 基线LDCT和miRNA将参与者分为四组:CT-/MSC-(n=2664;64.7%)、CT-/MSC+(n=800;19.4%)、CT+/MSC-(n=446;10.8%)、CT+/MSC+(n=209;5.1%)。
- 按方案,CT-/MSC-组和CT-/MSC+组分别分配至3年和1年LDCT复查间隔;CT+参与者根据LDCT特征(独立于MSC结果)分配至1年或更短间隔。
主要发现
- CT+参与者4年肺癌发生率较CT-参与者高15.8倍(95%CI 10.34-24.05)。
- MSC+参与者4年肺癌发生率较MSC-参与者高2.0倍(95%CI 1.40-2.90);无证据表明MSC效应在CT+与CT-参与者间存在差异。
- 4年肺癌发生率:CT-/MSC-组0.8%、CT-/MSC+组1.1%、CT+/MSC-组10.8%、CT+/MSC+组20.1%。
- 5年肺癌死亡率:CT-/MSC-组0.5、CT-/MSC+组1.5、CT+/MSC-组4.2、CT+/MSC+组10.1。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Large randomized trials have demonstrated that lung cancer (LC) screening with low-dose computed tomography (LDCT) reduces LC mortality in heavy smokers. We previously showed in the MILD screening trial that the combination of a prespecified circulating microRNA (miRNA) signature classifier (MSC) and LDCT improves the accuracy of LDCT alone. The primary aim of the prospective BioMILD study was to assess the additional value of the blood MSC assay at the time of baseline LDCT with the goal of personalizing LC screening intervals. PATIENTS AND METHODS: The study enrolled 4119 volunteers from January 2013 to March 2016, with a median follow-up of 5.3 years. Baseline LDCT and miRNAs stratified participants into four groups: CT-/MSC- (n = 2664; 64.7%); CT-/MSC+ (n = 800; 19.4%); CT+/MSC- (n = 446; 10.8%); and CT+/MSC+ (n = 209; 5.1%). As per the protocol, those in the CT-/MSC- and CT-/MSC+ groups were allocated to LDCT repeat at 3-year and 1-year intervals; CT+ participants were allocated for 1-year or earlier intervals on the basis of LDCT features independent of MSC results. RESULTS: CT+ participants had a 15.8-fold higher 4-year LC incidence than CT- participants (95% confidence interval 10.34-24.05), and MSC+ participants had a 2.0-fold higher 4-year LC incidence than MSC- participants (95% confidence interval 1.40-2.90); there was no evidence that the MSC effect differed between CT+ and CT- participants. LC incidence at 4 years was 0.8% in CT-/MSC-, 1.1% in CT-/MSC+, 10.8% in CT+/MSC-, and 20.1% in CT+/MSC+ participants. LC mortality rates at 5 years in the four risk groups were 0.5 in CT-/MSC-, 1.5 in CT-/MSC+, 4.2 in CT+/MSC-, and 10.1 in CT+/MSC+. CONCLUSION: The combined use of LDCT and blood miRNAs at baseline predicts individual LC incidence and mortality, with a major effect of MSC for LDCT-positive individuals. These findings may have important implications in personalizing screening intervals.
引用
- Pastorino U, Boeri M, Sestini S, et al. Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial. Ann Oncol. 2022. PMID: 35091076. doi:10.1016/j.annonc.2022.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。